Intermediate immune deficiency is defined by a CD4 cell count between
500/mu L and 200/mu L. This phase is one of increasing therapeutic int
ervention, mostly for minor infections of skin and mucous membranes an
d mostly manageable within general practice. Most people with HIV begi
n antiretroviral therapy during this phase. Regular monitoring of CD4
cell count is essential for making appropriate therapeutic decisions a
nd for determining prognosis.